# EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study

> **NCT03877848** · — · COMPLETED · sponsor: **Medinol Ltd.** · enrollment: 319 (actual)

## Conditions studied

- Coronary Stenosis

## Interventions

- **DEVICE:** Percutaneous Coronary Intervention (PCI)

## Key facts

- **NCT ID:** NCT03877848
- **Lead sponsor:** Medinol Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-06
- **Primary completion:** 2021-06-10
- **Final completion:** 2021-06-10
- **Target enrollment:** 319 (ACTUAL)
- **Last updated:** 2021-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03877848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03877848, "EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03877848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*